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Requirements of Circulatory Support During Liver Transplantation:
Are Patients With Familial Amyloidosis Different From Other Patients?
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FAMILIAL amyloidotic polyneuropathy (FAP) is a ge-netic dominant disease with a meaningful prevalence
in Portugal, Sweden, and Japan. A large number of bio-
chemistry anomalies could underlie this disease but by far
the most frequent is the transthyretin methionine 30 anom-
aly (FAP ATTR Met 30)1 whose symptoms start in adult
age and death ensues commonly 10 to 15 years after the
initial complaints. Liver transplantation is the only therapy
that has proved to stop this disease. As opposed to trans-
plant recipients with liver diseases, FAP patients present
without preoperative coagulation disorders and portal hy-
pertension, and the transplant tends to be technically easier,
with less blood loss and shorter operating time.2,3 Never-
theless the circulatory involvement is always present in the
natural course of this disease with autonomic dysfunction
being a characteristic finding and cardiac arrhythmias and
diastolic dysfunction being frequently observed.4 A high
incidence of severe hypotension is reported during liver
transplant in FAP2,5 and rhythm and intracardiac conduc-
tion anomalies have also been reported as a troublesome
problem during FAP anesthesia.6 The aim of this study was
to assess the intraoperative interventions on the circulatory
system and to correlate them with the findings of preoper-
ative routine examinations and intra-operative events.
PATIENTS
Group I included all 90 FAP ATTR Met 30 recipients of first liver
transplant during a 7-year period, 50 male and 40 female, with age
of 35.6 6 7.2 years, weight of 56.4 6 11.9 kg, body mass index
(BMI) of 20.8 6 4.1 kg/m2, disease duration (since the first
symptom) of 4.8 6 2.5 years, and a neurologic score of 33.9 6 12.6
in the scale of Macedo and col. Group II included all the 125 adults
(79 male, 46 female) with other diseases that received a first liver
transplant during the same period. Groups were not different with
regard to height and sex. Group II was older (42.3 6 12.8 years,
P , .001), and had a greater weight (65.7 6 12.0 kg, P , .001) and
BMI (23.8 6 4.3 kg/m2, P , .001). Hematologic and liver function
tests were normal in group I. Group II presented lower hemoglobin
(P , .001), fibrinogen (P , .001), and albumin (P , .001) and
higher prothrombin time (P , .001), direct (P , .001) and total
bilirubin (P , .001), AST (P , .001), ALT (P , .001), and
creatinine (P , .001). The transplant was done by classic technique
in 27 patients (30.0%) of group I and 39 (31.2%) of group II
(P 5 ns) and by piggy-back technique in the remaining. Seventeen
patients (18.9%) in group I and none in group II had a permanent
pacemaker.
METHOD
Anaesthesia, monitoring, and circulatory support protocols were
identical in the two groups and did not change during the years of
the study. Low-dose dopamine (3 mg/kg/min or less) was used in all
patients. Higher doses of dopamine were used as a first line
circulatory support. Dobutamine was used to treat low cardiac
output with adequate filling pressures and phenylephrine to treat
vasodilatation. Antiarrhythmic agents or vasodilators were used as
standard in general practice. Emergency transcutaneous pacing was
always available. Group I values were compared with group II
values by Mann-Whitney U test or chi-square test followed by
Fisher test, as appropriate. Within each group, if one drug was used
in a number of patients that allowed subsequent statistics, patients
that used it and patients that did not use it were compared with the
same statistical tests. Data as mean 6 standard deviation.
RESULTS
Venovenous bypass was used in 31.1% of group I and
33.6% of group II (P 5 ns). Group I patients needed 5.2 6
9.4 units of red blood cells (RBC), 12.7 6 16.6 units of fresh
frozen plasma (FFP), and 3.4 6 8.9 units of platelets. Blood
products consumption was significantly higher in group II:
13.1 6 12.7 units of RBC (P , .001), 26.4 6 21.4 units of
FFP (P , .001), and 9.0 6 8.6 units of platelets (P , .001).
Except for low-dose dopamine, at least one sympathomi-
metic drug was used in 75.6% of group I and 38.4% of
group II patients (P , .001). Dopamine (5 mg/kg/min or
more), dobutamine, phenylephrine, and epinephrine were
respectively used in 43.3%, 2.2%, 48.9%, and 7.8% of group
I patients. The respective values in group II patients were
27.2% (P , .05), 12.8% (P 5 ns), 3.2% (P , .001), and
4.0% (P 5 ns). Lidocaine was used in 7.8% of group I and
3.2% of group II patients (P 5 ns). Norepinephrine,
digoxin, verapamil, amiodarone, sodium nitroprusside, or
nitroglycerine were used in a maximum of one patient in
each group (P 5 ns). Emergency pacing was never used.
Within group II, the patients that needed inotropic
drugs had lower albumin (P , .05) and higher creatinine
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(P , .05) in the preoperative period and consumed more
RBC (15.0 6 11.3 vs 12.0 6 13.3 units, P , .05) and total
number of blood products (69.8 6 44.3 vs 55.2 6 49.9
units, P , .05) than the remaining patients of the same
group. Within group I, we are unable to find any differ-
ence between the patients that needed sympathomimet-
ric drugs and the patients that did not require its use.
DISCUSSION
Our study showed that FAP patients needed more pharma-
cologic support of the circulation during liver transplanta-
tion than the patients with other diseases and these differ-
ences were particularly important concerning pure
vasoconstrictor drugs. The high percentage of FAP recipi-
ents who needed phenylephrine and the low percentage
that needed dobutamine certainly reflects a high incidence
of sudden vasodilatation during their transplants, and also
the rarity of low cardiac output as consequence of inappro-
priate contractility, according to previous reports.2,5
Regarding group II, some evidences suggested that the
intraoperative use of sympathomimetic drugs was related to
poor preoperative condition (lower albumin, higher creati-
nine) and higher blood loss during surgery. In contrast,
similar relations were not observed in group I. We found
the need for drugs as independent of blood loss, nutritional
condition, or neurologic score, suggesting a particular role
of the circulatory involvement itself. The high number of
patients that needed vasoconstrictors, including patients in
very early stages of the disease, and the finding that this
need is not related to the duration of the disease suggested
that conditions that predispose to hypotension appear early
in the course of the disease.
Pacing deserves a particular discussion as it could be an
option to use a transvenous pacemaker in all FAP liver
transplants.6,7 In our series, more than 80% of patients did
not have any kind of pacemaker during the transplantation
and no need for emergency pacing was observed. We
cannot exclude that severe bradyarrhythmias could be a risk
during liver transplantation for FAP, but we can certainly
exclude that they constitute a source of frequent complica-
tions when the patients with indication for permanent
pacemaker had their pacemakers implanted before the
surgery.
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